Los Angeles, USA, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Recent Clinical Trials on the Treatment of Myocardial Infarction | New Drugs to Launch Soon

Approximately 40+ key companies are developing therapies for Myocardial Infarction. Idorsia Pharmaceuticals has its Myocardial Infarction drug in the most advanced stage (Phase III).

DelveInsights Myocardial Infarction Pipeline Insight report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in the Myocardial Infarction pipeline landscapes. It comprises Myocardial Infarction pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Myocardial Infarction therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Myocardial Infarction pipeline products.

Some of the key takeaways from the Myocardial Infarction Pipeline Report

Get an overview of pipeline landscape @ Myocardial Infarction Clinical Trials Analysis

Myocardial Infarction is a term used for an event of a heart attack due to the formation of plaques in the arteries interior walls, resulting in reduced blood flow to the heart and injuring heart muscles because of lack of oxygen supply.

Myocardial Infarction Emerging Drugs

CSL 112 is a novel apolipoprotein A-I infusion therapy to potentially reduce the risk of major adverse cardiovascular events (MACE) in patients with Acute Coronary Syndrome (ACS). Currently, it is in the Phase III stage of clinical trial evaluation to treat Acute Coronary Syndrome.

Idorsia is developing selatogrel, a potent, fast-acting, reversible, and highly selective P2Y12 receptor antagonist, for single subcutaneous self-administration to treat a suspected AMI in patients with a history of AMI. Currently, it is in the Phase III stage of clinical trial evaluation to treat AMI.

FDY-5301 is a patented elemental reducing agent-containing sodium iodide. Preclinical studies of FDY-5301 have shown its ability to decrease cardiac and skeletal muscle injury. Phase 1 data show no signs of toxicity in healthy subjects. Phase 2 data suggest a reduction in infarct size and improved cardiac function in patients treated with FDY-5301 after suffering an acute myocardial infarction (AMI).

Zalunfiban (RUC-4), a next-generation GPI, is specifically designed to be administered subcutaneously to stop platelet aggregation for a first-point-of-medical contact treatment to enhance outcomes for STEMI patients. Currently, it is in Phase II stage of clinical trial evaluation to treat ST-segment Elevation Myocardial Infarction.

For further information, refer to the detailed report @ Myocardial Infarction Pipeline Therapeutics

Scope of Myocardial Infarction Pipeline Drug Insight

Myocardial Infarction Therapies Late-stage (Phase III) Myocardial Infarction Therapies Mid-stage (Phase II) Myocardial Infarction Therapies Early-stage (Phase I) Myocardial Infarction Preclinical stage and Discovery candidates Discontinued and Inactive candidates

Cholesterol modulators; Free radical scavengers Purinoceptor P2Y12 antagonists GPIIb-IIIa antagonists LDL receptor modulators Inflammasome inhibitors Interleukin inhibitors NLRP3 protein inhibitors

Peptides Monoclonal antibodies Small molecules Polymer Gene therapy

Parenteral Intravenous Oral Subcutaneous

Monotherapy Combination Mono/Combination

Key Questions regarding Current Myocardial Infarction Treatment Landscape and Emerging Therapies Answered in the Pipeline Report

Table of Contents

Get a customized pipeline report @ Myocardial Infarction Drugs Pipeline Report

Other Reports

Browse Blog Posts

About DelveInsightDelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides Healthcare Consulting services comprising credible market analysis that will help accelerate the business growth and overcome challenges with a practical approach.

Visit link:

Recent Clinical Trials on the Treatment of Myocardial Infarction - GlobeNewswire

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *